Technology | ECG | August 08, 2017

AUM Cardiovascular Receives FDA Approval for CADence ECG Device

Reusable handheld device analyzes acoustic data from patient’s heart to help physicians noninvasively detect physiological and pathological heart murmurs

AUM Cardiovascular Receives FDA Approval for CADence ECG Device

August 8, 2017 — AUM Cardiovascular announced it has received clearance from the U.S. Food and Drug Administration (FDA) for CADence, a non-invasive acoustic and electrocardiogram (ECG) device designed to help physicians detect physiological and pathological heart murmurs.

The reusable, non-invasive, radiation-free handheld device, which is now available in the United States, records sounds originating from the patient's heart. Powered by a proprietary algorithm, special software crunches the acoustic data that is presented in a physician's report. The report allows a physician to determine the state of the patient's cardiovascular health. AUM also plans release of algorithms that crunch the same data to determine if arteries are clogged with plaque, a condition known as stenosis.

For primary care doctors, stenosis is particularly hard to detect because patients do not exhibit noticeable symptoms. Normal screening methods — measuring blood pressure and low-density lipoprotein (LDL) — are not good predictors of stenosis. Computed topography, magnetic resonance imaging and ultrasound can spot stenosis by measuring everything from thickness of artery walls to calcium deposits. But such technologies are expensive.

According to AUM's Turbulence clinical study, CADence performs just as well as a single-photon emission computed tomography (SPECT) nuclear stress test in ruling out obstructive coronary artery disease (CAD) in patients with chest pain and risk factors. AUM is pursuing clearance from FDA to market CADence for detection of CAD.

"The CADence system has the potential to dramatically enhance our ability to rule-out significant coronary artery disease and efficiently triage patients needing additional testing," said Jay Thomas, M.D., an interventional cardiologist at Harbor-UCLA Medical Center in Los Angeles, who oversaw the study.

"CADence is an exciting example of how novel technology will revolutionize patient care," Thomas said. "It is a rapid, cost-effective, radiation-free way to evaluate selected patients with chest pain.  The need for something like CADence is quite obvious considering how we have managed chest pain testing for the last twenty years."

For more information:

Related Content

Sedentary Lifestyle Cancels Out Heart Benefits of Normal Weight
News | Cardiac Diagnostics | January 09, 2019
January 9, 2019 — Researchers at the University of Florida have found that low levels of physical activity can put he
Livongo Launches Applied Health Signals Product Category
News | Cardiac Diagnostics | November 30, 2018
Healthcare technology company Livongo recently announced the launch of its Applied Health Signals product category,...
HHS Releases Second Edition of Physical Activity Guidelines for Americans. #AHA2018 #AHA18
News | Cardiac Diagnostics | November 14, 2018
The U.S. Department of Health and Human Services (HHS) released the second edition of the Physical Activity Guidelines...
ACC and AHA Release Updated Cholesterol Guidelines for 2018. #AHA18 #AHA2018
Feature | Cardiac Diagnostics | November 13, 2018
November 13, 2018 — New cholesterol guidelines from the American Heart Association (AHA) and the American College of
AMI READMITS Score Predicts Heart Attack Patients at High Readmission Risk
News | Cardiac Diagnostics | October 09, 2018
Tracking just seven factors of heart attack patients when they are first admitted to the hospital can help flag those...
Siemens Healthineers Showcases New In Vivo and In Vitro Cardiovascular Solutions at TCT 2018
News | Cardiac Diagnostics | September 21, 2018
At the 2018 Transcatheter Cardiovascular Therapeutics (TCT) conference, Sept. 21-25 in San Diego, Siemens Healthineers...
Weight Loss Drug Does Not Increase Cardiovascular Events
News | Cardiac Diagnostics | August 31, 2018
A weight loss drug does not increase cardiovascular events, according to late breaking results from the CAMELLIA-TIMI...
Acarix Presents CADScor System at ESC 2018
News | Cardiac Diagnostics | August 27, 2018
Acarix AB’s ultra-sensitive acoustic CADScor System for coronary artery disease risk assessment will be on display at...
NIH Ending Funding for Moderate Alcohol and Cardiovascular Health Trial
News | Cardiac Diagnostics | August 24, 2018
The National Institutes of Health announced in June it plans to end funding to the Moderate Alcohol and Cardiovascular...
Study Shows Multiple Benefits of Patient-to-Patient Connectivity in Familial Chylomicronemia Syndrome
News | Cardiac Diagnostics | August 07, 2018
Akcea Therapeutics Inc., an affiliate of Ionis Pharmaceuticals Inc., announced the publication of results from the...
Overlay Init